Bisphosphonate therapy for spinal aneurysmal bone cysts

ConclusionsBisphosphonate therapy can be used as the definitive treatment of spinal ABCs, except in patients with instability or progressive neurology, where surgical intervention is required. Clinicians should expect a patients symptoms to rapidly improve, their bone oedema to resolve by 3  months and their lesion to partially or completely ossify by 6–12 months.
Source: European Spine Journal - Category: Orthopaedics Source Type: research

Related Links:

Resumo O objetivo deste artigo é medir a prevalência e identificar fatores associados à dor lombar intensa (DL intensa) entre parturientes do município de Rio Grande, RS, Brasil, em 2013. Questionário padronizado aplicado por entrevistadoras previamente treinadas em até 48 horas após o parto. Realizou-se análise multivari ável utilizando regressão de Poisson tendo a razão de prevalência como medida de efeito. Dentre as 2685 parturientes incluídas no estudo, 51,2% referiram dor lombar gestacional e 27,3% tinham DL intensa, com maior pro...
Source: Ciencia e Saude Coletiva - Category: Occupational Health Source Type: research
ConclusionsA successful model was built predicting ODI MCID. Most important predictors were not modifiable surgical parameters, indicating that baseline clinical and radiographic status is a critical factor for reaching ODI MCID.Level of EvidenceLevel II.
Source: Spine Deformity - Category: Orthopaedics Source Type: research
The system is the only percutaneous PNS system cleared by the FDA and is indicated for up to 60 days in the back and/or extremities for both chronic and acute pain.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
The FDA has approved SPR Therapeutics’ (Cleveland) Sprint endura (single lead) and extensa (dual lead) peripheral nerve stimulation (PNS) systems. The minimally invasive Sprint system is the only FDA-approved percutaneous PNS system that is indicated for up to 60 days in the back and/or extremities for both chronic and acute pain and is the industry’s only dual lead capable PNS platform, according to the company. Get the full story on our sister site, Medical Design &Outsourcing. The post SPR Therapeutics’ new PNS system wins FDA nod appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Blog Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Pain Management SPR Therapeutics Source Type: news
Conclusion: Primary healthcare physicians working in one health system in Riyadh had a higher than expected adherence to referral guidelines for back pain related red flags. PMID: 30106424 [PubMed - in process]
Source: Saudi Medical Journal - Category: Middle East Health Tags: Saudi Med J Source Type: research
This study examined whether ANXA1 prevented remifentanil-caused OIH through modulating CXCL12 and NMDAR pathway in rats. Acute exposure to remifentanil induced mechanical allodynia and thermal hyperalgesia, which was accompanied by the increase of spinal ANXA1 and CXCL12/CXCR4 expression. Central injection of Anxa12-26 attenuated behavioral OIH in a dose-dependent manner, facilitated ANXA1 production, and inhibited up-regulation of CXCL12/CXCR4 level and NR2B-containing NMDAR phosphorylation. Moreover, pretreatment with AMD3100 reduced hyperalgesia and NR2B-containing NMDAR phosphorylation. Also, exogenous CXCL12 elicited ...
Source: Neuroscience Research - Category: Neuroscience Source Type: research
ConclusionThe presented sacral SDAVF case is unique as the patient presented with thoracic pain, mild lower limb weakness and sensory changes. Thorough knowledge regarding sacral SDAVFs will enable clinicians and neuroradiologists to diagnose the disease in the early stages and offer prompt treatment.
Source: Interdisciplinary Neurosurgery - Category: Neurosurgery Source Type: research
Study Design. Multicenter, prospective study of consecutive adult spinal deformity (ASD) patients. Objective. To evaluate back and leg pain as a combined score in ASD and compare their relative and cumulative correlations with health-related quality of life (HRQOL) and sagittal parameters. Summary of Background Data. Pain and disability are commonly reported in patients with ASD. This can affect their back, their legs or both. ASD-associated pain has been correlated with numerous HRQOL scores and radiological parameters. Methods. Preoperative pain intensity was assessed with a Numerical Rating Scale (NRS) for in...
Source: Spine - Category: Orthopaedics Tags: Deformity Source Type: research
Study Design. Retrospective analysis wherein 103 patients were considered, and 76 patients were included: 49 were classified as chronic non-specific low back pain (CNSLBP) (Study group) and 27 had identifiable cases of specific chronic low back pain (LBP) (Control group). Objective. Elucidate markers of systemic inflammation in patients with CNSLBP. Summary of Background Data. Mechanisms of LBP are poorly understood. Pro-inflammatory cytokines are increased in obesity and involved with pain modulation; we previously proposed a theoretical model of their mediating role in LBP. Methods. Demographic information was...
Source: Spine - Category: Orthopaedics Tags: Epidemiology Source Type: research
Study Design. Longitudinal observational study. Objective. To investigate the association between the duration of pain at baseline and the clinical outcomes of patients with low back pain (LBP) enrolled on the North East of England Regional Back Pain and Radicular Pain Pathway (NERBPP). Summary of Background Data. The NERBPP is a clinical pathway based upon National Institute for Health and Care Excellence (NICE) guidelines (2009) for LBP of
Source: Spine - Category: Orthopaedics Tags: Health Services Research Source Type: research
More News: Back Pain | Brain | CT Scan | Neurology | Orthopaedics | Pain | Pain Management | PET Scan | Study | X-Ray